PRINCETON, N.J. and FORT LEE, N.J. Oct. 17, 2023 (GLOBE NEWSWIRE) -- Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma), one of China™s largest pharmaceutical companies based on market...
Camrelizumab in Combination with Rivoceranib (Apatinib) Significantly Prolonged Overall Survival and Progression-Free Survival vs Sorafenib in Patients with Unresectable Hepatocellular Carcinoma in a Multinational Phase 3 Trial, a Joint Program with Elevar Therapeutics
PARIS, Sept. 10, 2022 /PRNewswire/ -- Jiangsu Hengrui Pharmaceuticals Co., Ltd., one of the largest biopharmaceutical companies headquartered in China, today announced top-line results from the phase 3 study of camrelizumab (anti-PD1 checkpoint inhibitor) combined with rivoceranib (apatinib) vs. sorafenib as a first-line therapy for uHCC. Camrelizumab plus rivoceranib significantly prolonged overall survival (OS) and progression-free survival (PFS), and improved overall response rate (ORR) vs. sorafenib, a standard first-line treatment for uHCC.
Dalpiciclib in Combination with Letrozole or Anastrozole Significantly Improved Progression-free Survival in Systemic Treatment-naive, HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer
Hengrui Pharma Announces Frontline Camrelizumab in Combination with Rivoceranib Significantly Improved Progression-free Survival and Overall Survival in a Global Phase 3 Trial in Advanced Hepatocellular Carcinoma
Jiangsu Hengrui subsidiary Reistone and Shanghai Laekna raise a combined $161m for their innovative candidates.
Jiangsu Hengrui has launched Luzsana Biotechnology to serve as an arm to develop and deliver therapeutics outside of the Chinese market. Serving as a wholly owned subsidiary of Hengrui Pharma, Luzsana will be provided Hengrui’s pipeline of programs, spanning over 250 clinical studies, to develop and eventually commercialize.
Phase II results of vunakizumab in patients with moderate-to-severe plaque psoriasis published in the Journal of the American Academy of Dermatology
Thursday, Jiangsu Hengrui Medicine said a global phase 3 trial of its PD-1 inhibitor camrelizumab and VEGFR inhibitor apatinib, also known as rivoceranib, has hit its goals in newly diagnosed patients of liver cancer. The combination topped Bayer’s Nexavar at extending patients’ lives and preventing disease progression or death, Hengrui said in a filing (PDF, Chinese) to the Shanghai Stock Exchange.